Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase Ib Clinical Study Evaluating the Safety, Tolerability, and Efficacy of IN10018 in Combination With Dalpiciclib in Participants With Progressive Meningiomas

NCT07652762 is registered in ClinicalTrials.gov with Capital Medical University as lead sponsor.

NCT NCT07652762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07652762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase Ib Clinical Study Evaluating the Safety, Tolerability, and Efficacy of IN10018 in Combination With Dalpiciclib in Participants With Progressive Meningiomas
Lead sponsor
Capital Medical University
Phase
Phase 1
Overall status
Recruiting
Start date
August 31, 2026
Completion date
August 31, 2029
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cdk4/6 inhibitor, meningioma